Cargando…
Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report
BACKGROUND: Severe hypocalcemia may lead to life-threatening arrhythmias. Denosumab is an effective treatment for osteoporosis that allows long intervals between doses. However, there is a risk of hypocalcemia in some patients. Due to the long half-life of denosumab, emergency physicians caring for...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463425/ https://www.ncbi.nlm.nih.gov/pubmed/37635211 http://dx.doi.org/10.1186/s12245-023-00529-6 |
_version_ | 1785098228928086016 |
---|---|
author | Okuno, Fumito Ito-Masui, Asami Hane, Atsuya Maeyama, Keiko Ikejiri, Kaoru Ishikura, Ken Yanagisawa, Masashi Dohi, Kaoru Suzuki, Kei |
author_facet | Okuno, Fumito Ito-Masui, Asami Hane, Atsuya Maeyama, Keiko Ikejiri, Kaoru Ishikura, Ken Yanagisawa, Masashi Dohi, Kaoru Suzuki, Kei |
author_sort | Okuno, Fumito |
collection | PubMed |
description | BACKGROUND: Severe hypocalcemia may lead to life-threatening arrhythmias. Denosumab is an effective treatment for osteoporosis that allows long intervals between doses. However, there is a risk of hypocalcemia in some patients. Due to the long half-life of denosumab, emergency physicians caring for patients presenting with symptoms of hypocalcemia may not be aware of the medication, and adverse effects may last longer. CASE PRESENTATION: A 55-year-old woman with a history of systemic lupus erythematosus (SLE) and anxiety disorder called for an ambulance for symptoms of hyperventilation and muscle cramps. After evaluation at the local hospital, she developed pulseless ventricular tachycardia and was resuscitated by defibrillation by the hospital staff. After conversion to sinus rhythm, she was transported to a tertiary center. Upon arrival, pulseless ventricular tachycardia occurred again, and veno-arterial extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pumping (IABP) were implemented. Laboratory results showed severe hypocalcemia (corrected calcium level of 5.3 mg/dL) whereupon intravenous calcium supplementation was started. She had received the first dose of denosumab (60 mg) by subcutaneous injection 24 days prior to hospitalization. She was eventually weaned from ECMO and IABP support. CONCLUSION: Cardiac arrest due to hypocalcemia is relatively rare but can be fatal. In the present case, hyperventilation may have acutely exacerbated pre-existing hypocalcemia, leading to ventricular tachycardia. The patient had a slightly decreased serum calcium level prior to denosumab. Close monitoring may be preferable after the primary dose of denosumab in selected patients. Emergency physicians caring for patients who may be suffering from symptoms/signs of hypocalcemia must be mindful of medications that have long half-lives and affect electrolyte balance when treating fatal arrhythmia due to hypocalcemia. |
format | Online Article Text |
id | pubmed-10463425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-104634252023-08-30 Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report Okuno, Fumito Ito-Masui, Asami Hane, Atsuya Maeyama, Keiko Ikejiri, Kaoru Ishikura, Ken Yanagisawa, Masashi Dohi, Kaoru Suzuki, Kei Int J Emerg Med Case Report BACKGROUND: Severe hypocalcemia may lead to life-threatening arrhythmias. Denosumab is an effective treatment for osteoporosis that allows long intervals between doses. However, there is a risk of hypocalcemia in some patients. Due to the long half-life of denosumab, emergency physicians caring for patients presenting with symptoms of hypocalcemia may not be aware of the medication, and adverse effects may last longer. CASE PRESENTATION: A 55-year-old woman with a history of systemic lupus erythematosus (SLE) and anxiety disorder called for an ambulance for symptoms of hyperventilation and muscle cramps. After evaluation at the local hospital, she developed pulseless ventricular tachycardia and was resuscitated by defibrillation by the hospital staff. After conversion to sinus rhythm, she was transported to a tertiary center. Upon arrival, pulseless ventricular tachycardia occurred again, and veno-arterial extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pumping (IABP) were implemented. Laboratory results showed severe hypocalcemia (corrected calcium level of 5.3 mg/dL) whereupon intravenous calcium supplementation was started. She had received the first dose of denosumab (60 mg) by subcutaneous injection 24 days prior to hospitalization. She was eventually weaned from ECMO and IABP support. CONCLUSION: Cardiac arrest due to hypocalcemia is relatively rare but can be fatal. In the present case, hyperventilation may have acutely exacerbated pre-existing hypocalcemia, leading to ventricular tachycardia. The patient had a slightly decreased serum calcium level prior to denosumab. Close monitoring may be preferable after the primary dose of denosumab in selected patients. Emergency physicians caring for patients who may be suffering from symptoms/signs of hypocalcemia must be mindful of medications that have long half-lives and affect electrolyte balance when treating fatal arrhythmia due to hypocalcemia. Springer Berlin Heidelberg 2023-08-28 /pmc/articles/PMC10463425/ /pubmed/37635211 http://dx.doi.org/10.1186/s12245-023-00529-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Okuno, Fumito Ito-Masui, Asami Hane, Atsuya Maeyama, Keiko Ikejiri, Kaoru Ishikura, Ken Yanagisawa, Masashi Dohi, Kaoru Suzuki, Kei Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title | Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title_full | Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title_fullStr | Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title_full_unstemmed | Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title_short | Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
title_sort | severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463425/ https://www.ncbi.nlm.nih.gov/pubmed/37635211 http://dx.doi.org/10.1186/s12245-023-00529-6 |
work_keys_str_mv | AT okunofumito severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT itomasuiasami severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT haneatsuya severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT maeyamakeiko severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT ikejirikaoru severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT ishikuraken severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT yanagisawamasashi severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT dohikaoru severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport AT suzukikei severehypocalcemiaafterdenosumabtreatmentleadingtorefractoryventriculartachycardiaandvenoarterialextracorporealmembraneoxygenationsupportacasereport |